Knockdown of Adhesion-Regulating Molecule 1 Inhibits Proliferation in HL60 Cells

Acta Haematologica

Volumn 134, Issue 2, 2015, Pages 88-100

  Zheng, Xiaohui ^a   Guo, Yafei ^a   Chen, Yingying ^a   Chen, Meilin ^a   Lin, Zhenxin ^a   Wu, Yong ^a   Chen, Yuanzhong ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Acute leukemia; Adhesion regulating molecule 1; Suppressed HL60 cell proliferation

Indexed keywords

ADHESION REGULATING MOLECULE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SYNAPTOTAGMIN I; UBIQUITIN; UNCLASSIFIED DRUG; ADRM1 PROTEIN, HUMAN; CD34 ANTIGEN; MEMBRANE PROTEIN; SMALL INTERFERING RNA; TUMOR PROTEIN;

ACUTE LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH ASSAY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; GROWTH CURVE; HL 60 CELL LINE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BLOOD; CELL MOTION; COMPARATIVE STUDY; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; LEUKEMIA; LEUKEMIA, PROMYELOCYTIC, ACUTE; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANTIGENS, CD34; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; G0 PHASE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HL-60 CELLS; HUMANS; LEUKEMIA; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTES, MONONUCLEAR; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 84928158647     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000369916     Document Type: Article

References (27)

1. Jørgensen JP, Lauridsen AM, Kristensen P, Dissing K, Johnsen AH, Hendil KB, Hartmann-Petersen R: Adrm1, a putative cell adhesion regulating protein, is a novel proteasome-associated factor. J Mol Biol 2006; 360: 1043-1052.
2. Qiu XB, Ouyang SY, Li CJ, Miao S, Wang L, Goldberg AL: hRpn13/ADRM1/GP110 is a novel proteasome subunit that binds the deubiquitinating enzyme, UCH37. EMBO J 2006; 25: 5742-5753.
3. Husnjak K, Elsasser S, Zhang N, Chen X, Randles L, Shi Y, Hofmann K, Walters KJ, Finley D, Dikic I: Proteasome subunit Rpn13 is a novel ubiquitin receptor. Nature 2008; 453: 481-488.
4. Schreiner P, Chen X, Husnjak K, Randles L, Zhang N, Elsasser S, Finley D, Dikic I, Walters KJ, Groll M: Ubiquitin docking at the proteasome through a novel pleckstrin-homology domain interaction. Nature 2008; 453: 548-552.
5. Besche HC, Sha Z, Kukushkin NV, Peth A, Hock EM, Kim W, Gygi S, Gutierrez JA, Liao H, Dick L, Goldberg AL: Autoubiquitination of the 26S proteasome on Rpn13 regulates breakdown of ubiquitin conjugates. EMBO J 2014; 33: 1159-1176.
6. Chen X, Lee BH, Finley D, Walters KJ: Structure of proteasome ubiquitin receptor hRpn13 and its activation by the scaffolding protein hRpn2. Mol Cell 2010; 38: 404-415.
7. Hamazaki J, Iemura S, Natsume T, Yashiroda H, Tanaka K, Murata S: A novel proteasome interacting protein recruits the deubiquitinating enzyme UCH37 to 26S proteasomes. EMBO J 2006; 25: 4524-4536.
8. Yao T, Song L, Xu W, DeMartino GN, Florens L, Swanson SK, Washburn MP, Conaway RC, Conaway JW, Cohen RE: Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1. Nat Cell Biol 2006; 8: 994-1002.
9. Jiao L, Ouyang S, Shaw N, Song G, Feng Y, Niu F, Qiu W, Zhu H, Hung LW, Zuo X, Eleonora Shtykova V, Zhu P, Dong YH, Xu R, Liu ZJ: Mechanism of the Rpn13-induced activation of Uch37. Protein Cell 2014; 5: 616-630.
10. Mazumdar T, Gorgun FM, Sha Y, Tyryshkin A, Zeng S, Hartmann-Petersen R, Jørgensen JP, Hendil KB, Eissa NT: Regulation of NFkappaB activity and inducible nitric oxide synthase by regulatory particle non-ATPase subunit 13 (Rpn13). Proc Natl Acad Sci U S A 2010; 107: 13854-13859.
11. Yang X, Miao X, Wen Y, Hu J, Dai W, Yin B: A possible connection between adhesion regulating molecule 1 overexpression and nuclear factor kappa B activity in hepatocarcinogenesis. Oncol Rep 2012; 28: 283-290.
12. Fejzo MS, Dering J, Ginther C, Anderson L, Ramos L, Walsh C, Karlan B, Slamon DJ: Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target. Genes Chromosomes Cancer 2008; 47: 873-883.
13. Tabach Y, Kogan-Sakin I, Buganim Y, Solomon H, Goldfinger N, Hovland R, Ke XS, Oyan AM, Kalland KH, Rotter V, Domany E: Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer. PLoS One 2011; 6:e14632.
14. Simins AB, Weighardt H, Weidner KM, Weidle UH, Holzmann B: Functional cloning of ARM-1, an adhesion-regulating molecule upregulated in metastatic tumor cells. Clin Exp Metastasis 1999; 17: 641-648.
15. Pilarsky C, Wenzig M, Specht T, Saeger HD, Grützmann R: Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 2004; 6: 744-750.
16. Sillars-Hardebol AH, Carvalho B, de Wit M, Postma C, Delis-van Diemen PM, Mongera S, Ylstra B, van de Wiel MA, Meijer GA, Fijneman RJ: Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumour Biol 2010; 31: 89-96.
17. Jang SH, Park JW, Kim HR, Seong JK, Kim HK: ADRM1 gene amplification is a candidate driver for metastatic gastric cancers. Clin Exp Metastasis 2014; 31: 727-733.
18. Chen W, Hu XT, Shi QL, Zhang FB, He C: Knockdown of the novel proteasome subunit Adrm1 located on the 20q13 amplicon inhibits colorectal cancer cell migration, survival and tumorigenicity. Oncol Rep 2009; 21: 531-537.
19. Fejzo MS, Anderson L, von Euw EM, Kalous O, Avliyakulov NK, Haykinson MJ, Konecny GE, Finn RS, Slamon DJ: Amplification target ADRM1: role as an oncogene and therapeutic target for ovarian cancer. Int J Mol Sci 2013; 14: 3094-3109.
20. Ravid T, Hochstrasser M: Diversity of degradation signals in the ubiquitin-proteasome system. Nat Rev Mol Cell Biol 2008; 9: 679-690.
21. Schwartz AL, Ciechanover A: Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol 2009; 49: 73-96.
22. Anchoori RK, Karanam B, Peng S, Wang JW, Jiang R, Tanno T, Orlowski RZ, Matsui W, Zhao M, Rudek MA, Hung CF, Chen X, Walters KJ, Roden RB: A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. Cancer Cell 2013; 24: 791-805.
23. Pacifico F, Leonardi A: NF-kappaB in solid tumors. Biochem Pharmacol 2006; 72: 1142-1152.
24. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M: NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 1999; 19: 2690-2698.
25. Hsia CY, Cheng S, Owyang AM, Dowdy SF, Liou HC: c-Rel regulation of the cell cycle in primary mouse B lymphocytes. Int Immunol 2002; 14: 905-916.
26. Kim DW, Gazourian L, Quadri SA, Romieu-Mourez R, Sherr DH, Sonenshein GE: The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene 2000; 19: 5498-5506.
27. Hinz M, Löser P, Mathas S, Krappmann D, Dörken B, Scheidereit C: Constitutive NFkappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 2001; 97: 2798-2807.